NB-5-MeO-DALT, also called 5-MeO-DALT BOC or NBoc-5-MeO-DALT, is an N-tert-butoxycarbonyl-protected derivative of 5-MeO-DALT. The protecting group is attached to the indole nitrogen at position 1. Despite the abbreviation, “NB” here does not mean N-benzyl: it refers to the N-Boc modification. The compound appeared in online research-chemical listings in 2022, but its pharmacology and effects in humans have not been established.
Chemistry and identification
The molecule retains the 5-methoxy-N,N-diallyltryptamine framework of 5-MeO-DALT, with a tert-butoxycarbonyl (Boc) group attached to the indole nitrogen. This makes it a protected derivative rather than a simple ring-substituted tryptamine. It has been listed in the oxalate salt form in market-monitoring records.
The AIPSIN monitoring bulletin published in August 2022 recorded offers for 5-MeO-DALT BOC and provided its proposed chemical name and structure. The bulletin classified it as an N-disubstituted tryptamine derivative and described the Boc group as a protective group commonly used in organic synthesis (AIPSIN, Recent Trends in the Identification of Psychoactive Substances, Issue 32, 2022).
Relationship to 5-MeO-DALT
The principal structural difference from 5-MeO-DALT is the Boc group on the indole nitrogen. In synthetic chemistry, Boc is used to temporarily protect nitrogen functionality and can be removed under suitable deprotection conditions. Its presence can change a molecule’s size, polarity and ability to interact with biological targets.
Market-monitoring material relayed claims that the protected compound could release 5-MeO-DALT under strong heating. Those claims were reported from commercial listings; they should not be confused with a peer-reviewed study demonstrating a predictable conversion under real-world conditions or in the human body.
Pharmacology
No direct receptor-binding or functional assay for NB-5-MeO-DALT was identified in the scientific literature reviewed here. In particular, there is no reliable compound-specific evidence establishing its activity at 5-HT2A, 5-HT1A or other serotonin receptors.
Research on the unprotected parent compound 5-MeO-DALT cannot fill this gap. A 2015 metabolism study examined 5-MeO-DALT itself in rat urine and human liver-enzyme systems, but it did not investigate the N-Boc derivative (Michely and colleagues, 2015).
Reported effects and human evidence
There are no controlled human studies or well-documented clinical case series establishing the subjective effects of NB-5-MeO-DALT. The few online descriptions often assume that, after conversion, the compound behaves like 5-MeO-DALT. Clinical pharmacokinetic or pharmacodynamic research has not validated that assumption.
Toxicology and research limitations
No compound-specific human metabolism study, acute toxicology assessment or long-term safety research was identified. It is not known whether the Boc group is removed to a meaningful extent in the body, what metabolites would be formed, or whether the intact molecule has independent biological activity.
The available record is therefore mainly chemical and market-monitoring evidence. A claim that NB-5-MeO-DALT is a prodrug of 5-MeO-DALT should remain qualified unless direct metabolic and human data become available.
Related tryptamines
NB-5-MeO-DALT is structurally related to 5-MeO-DALT and NB-5-MeO-MiPT. The two NBoc derivatives share the same indole N-protecting group, but retain different side-chain substitutions from their respective parent tryptamines.
NB-5-MeO-DALT Products
Scientific Data
Structured reference fields associated with this compound.